Triptorelin
Decapeptyl, Trelstar, Gonapeptyl, Pamorelin
A synthetic GnRH agonist decapeptide that suppresses gonadotropin and sex hormone production for treating prostate cancer, endometriosis, and precocious puberty.
Completed
NCT01942369
A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months
Ipsen
OBSERVATIONAL
Updated Dec 15, 2025
Unknown
PHASE3
NCT05972902
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
Beni-Suef University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT05286554
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support
Alexandria University
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT07242534
Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Fundacion Dexeus
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT05377684
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Ipsen
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE1, PHASE2
NCT04071574
Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
Lebanese University
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT07268794
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
Fudan University
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT05625087
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
UNICANCER
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT00461916
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin
Tehran University of Medical Sciences
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2, PHASE3
NCT04242017
Long-term Better Than Short-term ADT With Salvage RT
Universitaire Ziekenhuizen KU Leuven
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT02674178
FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women
Cairo University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01257425
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
Ipsen
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06922318
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
EARLY PHASE1
NCT03511196
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT05896566
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
ETOP IBCSG Partners Foundation
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2
NCT00444639
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
Ipsen
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2, PHASE3
NCT02685397
Management of Castration-Resistant Prostate Cancer with Oligometastases
Sir Mortimer B. Davis - Jewish General Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE3
NCT00415246
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
Ipsen
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2
NCT01374087
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
Ipsen
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT05982093
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
SOLTI Breast Cancer Research Group
INTERVENTIONAL
Updated Dec 15, 2025